HDAC9 and neoplasm: Collectively, the findings within this manuscript strongly argue that the rational coupling of pan-HDAC inhibitors to current immunotherapies could provide expanded response rates and improved outcomes for melanoma patients (and beyond), and that specific HDAC therapies may not be effective due to the overlapping regulatory mechanisms performed by the multitude of HDACs in human tumor cells.